ERBB2 and triple-negative breast carcinoma: Among these, 28.7% (75/256) involved (HR+), HER2(−) diagnoses, 15.1% (39/256) (HR+), HER2(+) diagnoses, 8.5% (22/256) (HR−), HER2(+) diagnoses, and 38.8% (100/256) involved triple-negative breast cancer (TNBC), including basal-like type.